louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02724475: Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Official title: Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Laser Ablation
Portal Vein Tumor Thrombus
Keywords: Laser Ablation
Portal Vein Tumor
Thrombus
Lead sponsor: Eastern Hepatobiliary Surgery Hospital
Sponsor class: OTHER
First posted: 2016-03-31
Enrollment: 180
Sex: ALL
Minimum age (years): 17
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC. The 5-year overall survival (OS) rates after hepatic resection were range from 25% to 45% and the incidence of portal vein tumor thrombus (PVTT) for intermediate and advanced hepatocellular carcinoma patients were as high as 60%-90%. At present, there is no effective treatment for patients with PVTT. Laser ablation (LA) showed a good performance in eliminating the PVTT and the three-dimensional conformal radiotherapy (3D-CRT) with γ Ray (γ-knife) can also be used to treat patients with PVTT. But there still lack of evidence-based research to compare the clinical outcome of 3D-CRT with γ Ray and LA. In view of this, we aim to implement a randomized controlled study to find out an effective treatment for intermediate and advanced hepatocellular carcinoma patients with PVTT based on evidence-based research.


Eligibility criteria: Inclusion Criteria:

1. Child-Pugh class B liver function；
2. Preoperative ECOG criteria score of 0-2;
3. Patients preoperatively diagnosed of hepatocellular carcinoma according to chest computed tomography (CT) and/or magnetic resonance imaging (MRI);
4. Tumor thrombus in the second-order or more peripheral branch of portal vein;
5. Tumor number ≤5 and the sum of largests tumor diameter ≤15 cm;
6. The expected survival time \>6 months.

Exclusion Criteria:

1. Other anticancer treatment before treatment
2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer
3. Patients with other diseases that may affect the treatment of this treatment
4. History of other malignant tumors
5. Patients who are participating in other clinical trials
6. Pregnant, lactating women

Primary outcomes:
measure: Toxic and side effects caused by 3D-CRT or LA
timeFrame: 3 years
measure: Postoperative complication
timeFrame: 3 years
measure: Overall survival
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Eastern hepatobilliary surgery hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT00250575: A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Official title: A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Keywords: Schizophrenia, treatment-resistant, clozapine
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-11-08
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

This study is not recruiting in the United States.

Detailed description: Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

Eligibility criteria: Inclusion Criteria:

* Diagnosed as schizophrenia
* Not responded to at least two atypical antipshychotics launched in Japan
* Inpatient

Exclusion Criteria:

* Low white blood cell count
* Significant heart diseases
* Diabetes mellitus

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Values of hematological tests during the 24 week treatment
measure: Incidence of hematological adverse events during the 24 week treatment
measure: Compliance to Clozapine Patient Monitoring System during the 24 week treatment
Secondary outcomes:
measure: Changes in the symptoms of psychosis every 4 weeks up to week 24
measure: Global change in severity of psychosis at baseline and week 12
measure: Global impression of change in the condition of patients at week 12 and 24
Other outcomes:
Locations:
city: Chiba
country: Japan
facility: Novartis Investigational Site
city: Fukuoka
country: Japan
facility: Novartis Investigative Site
city: Ishikawa
country: Japan
facility: Novartis Investigative Site
city: Osaka
country: Japan
facility: Novartis Investigative Site
city: Saga
country: Japan
facility: Novartis Investigative Site
city: Tokyo
country: Japan
facility: Novartis Investigative Site
city: Toyama
country: Japan
facility: Novartis Investigative Site
city: Yamanashi
country: Japan
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_CHAIR
References:
Clinical trial NCT03986775: Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
Official title: AFCRO-066: A Double-blinded, Randomized, Controlled, Acute, Cross-over Study to Determine the Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Keywords: Glycemic Index
Overweight
Endothelial function
carbohydrate
Lead sponsor: Beneo-Institute
Sponsor class: INDUSTRY
First posted: 2019-06-14
Enrollment: 80
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.


Eligibility criteria: Inclusion criteria:

* Subject is healthy at the time of pre-examination
* Subject has a BMI of 25 - 35 kg/m²
* Subject is aged 25 - 50 years at the time of pre-examination
* Signed written informed consent
* Inactive (IPAQ score \<1)
* Waist to Hip ratio ≥0.90 cm for males, ≥0.85 cm for females
* High-normo/Mild hypertensive (SBP: 130-159 mmHg / DBP: 80-99 mmHg)

Exclusion criteria:

* Use of medication interfering with RAAS, such as ACE-inhibitors,
* Advanced cardio-vascular disease (CVD),
* Severe kidney disorders (CKD),
* Diabetes mellitus, both type 1 and II diabetes,
* Pregnant, lactating or wish to become pregnant,
* Hypersensitivity to any of the components of the test product,
* Restricted diet (vegetarian)
* Thyroid disease
* Heavy Smokers (light smokers allowed)
* Lack of suitability for participation in the trial, for any medical reason, as judged by the PI.
* Excessive alcohol consumption (\>21 units/week for males \& \>14 units/week for females)

Primary outcomes:
measure: Brachial ultrasound FMD scan
timeFrame: Baseline, 60 minutes, 120 minutes, 180 minutes
Secondary outcomes:
measure: Postprandial glycemic response
timeFrame: Baseline, 60 minutes, 120 minutes, 180 minutes
measure: Postprandial insulin response
timeFrame: Baseline, 60 minutes, 120 minutes, 180 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06116175: Lateral Epicondylitis Continuous Radiofrequency Microtenotomy
Official title: Efficacy of Continuous Radiofrequency 60 Celsius Degree in Management of Chronic Lateral Epicondylitis Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tennis Elbow
Lead sponsor: Iraqi Board of medical specialties
Sponsor class: OTHER
First posted: 2023-11-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: prospective study measuring the outcome of continuous radio frequency 60 degree on lateral epicondylitis not responding to traditional ultrasound guided injection


Eligibility criteria: Inclusion Criteria:

* chronic tennis elbow no response to traditional injection ultrasound exam reveal swelling of common extensor tendon

Exclusion Criteria:

* complete tear of common extensor tendon implanted pace maker

Primary outcomes:
measure: decrease in pain score after CRF
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baghdad
country: Iraq
facility: Baghdad Medical City
Study officials:
References:
Clinical trial NCT04632875: Online Trial of Meditation and Behavior
Official title: Identifying Neural Correlates of Altruism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Meditation
Lead sponsor: Georgetown University
Sponsor class: OTHER
First posted: 2020-11-17
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates how different types of meditation may affect behaviors and emotions. The study is conducted entirely online and involves listening to 4-weeks of a guided meditation training. The meditation involves either Loving-Kindness or Relaxation techniques. The purpose of the study is to assess changes in behaviors and emotions using standard questionnaires, reports of real-world behavior, and online behavioral tasks. The overarching goal is to help clarify how mind-body practices may improve some aspects of well-being.


Eligibility criteria: Inclusion Criteria:

* Is a medically healthy individual
* Lives in the United States
* Has reliable internet access and the ability to join a Zoom video chat

Exclusion Criteria:

* Has experience with meditation or other mind-body practices
* Has a neurological disease
* Has a current psychiatric disorder
* Is on medication that affects the central nervous system (e.g. psychotropic drugs)
* Has recurrent or chronic pain
* Is pregnant or planning to become pregnant

Primary outcomes:
measure: Social functioning
timeFrame: 4-5 weeks
measure: Affective responses
timeFrame: 4-5 weeks
Secondary outcomes:
measure: Psychological well-being related to COVID-19
timeFrame: 4-5 weeks
Other outcomes:
Locations:
city: Washington
country: United States
facility: Georgetown University
state: District of Columbia
Study officials:
affiliation: Georgetown University
name: Abigail A Marsh, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01919775: Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution Magnetic Resonance (MR) Imaging Findings
Official title: Basal Forebrain Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution 3-dimensional (3D) Magnetic Resonance (MR) Imaging Findings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage
Cerebral Aneurysm
Amnesia
Lead sponsor: Tohoku University
Sponsor class: OTHER
First posted: 2013-08-09
Enrollment: 14
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with amnesia following surgical treatment of the ACoA aneurysm.

Brief summary: To clarify whether amnesia after treatment of anterior communicating aneurysm (ACoA)is related to infarcts caused by occlusion or damage of the perforating artery of the ACoA, we used 3.0-T 3D high resolution MR imaging to identify and localize infarcts in patients with amnesia following treatment of ACoA aneurysm.

Detailed description: Cohort register is made by experienced neuropsychologists in our institute.

MR imaging and data storage is in the department of diagnostic radiology of our institute.

MR images are evaluated by two neuroradiologists using a work station.

Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of Amnesia

Exclusion Criteria:

Severe decreased intellectual function

Primary outcomes:
measure: cerebral infarction identified and localized in the basal forebrain on MR imaging
timeFrame: within 15 months from the aneurysmal treatment(an expected average 4 months)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Diagnostic Radiology, Tohoku University, Graduate School of Medicine, Sendai, Japan
name: Shoki Takahashi, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06757075: Management of Postoperative Discomfort in Young Children Following Dental Rehabilitation Under General Anesthesia
Official title: A Comparison of Standard Dose of Ibuprofen Alone, Alternating, or Combined With Acetaminophen for the Management of Postoperative Discomfort in Young Children Following Dental Rehabilitation Under General Anesthesia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Pain, Postoperative
Keywords: Dental rehabilitation under general anesthesia (DRGA)
Dental surgery patients 4-6 years
Acetominophen
Ibuprofen
Pacing analgesics
Lead sponsor: Boston University
Sponsor class: OTHER
Collaborators: name: Franciscan Hospital For Children, INC.
First posted: 2025-01-03
Enrollment: 75
Sex: ALL
Minimum age (years): 4
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effectiveness of various oral analgesic regimens in minimizing post-operative pain and discomfort in young children following dental rehabilitation under general anesthesia (DRGA). In this randomized controlled trial, three analgesic regimens following DRGA in Franciscan Children's Hospital will be compared using both self-report and behavioral measures.

The analgesic therapies to be investigated are ibuprofen monotherapy, alternating ibuprofen and acetaminophen dual-therapy, and combined ibuprofen and acetaminophen dual-therapy. For the purposes of this study, combined therapy is defined as the simultaneous administration of acetaminophen and ibuprofen at regular intervals, whereas alternating therapy is defined as one analgesic (acetaminophen or ibuprofen) administered within a 3 hour interval of the other.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) I-II
* Requiring Oral Rehabilitation under General Anesthesia
* Possess legal guardians proficient in English
* Not have a history of any adverse/allergic reaction to nonsteroidal anti-inflammatory drugs (NSAIDs) or Acetaminophen

Exclusion Criteria:

* ASA III or IV
* Asthma diagnosis
* Contraindication to acetaminophen or ibuprofen

Primary outcomes:
measure: Dental discomfort assessed by the abbreviated DDQ-8
timeFrame: day of surgery, one pay post surgery, 2 days post surgery, 15 days post surgery
measure: Pain assessment based on the FLACC
timeFrame: day of surgery, one pay post surgery, 2 days post surgery, 15 days post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Brighton
country: United States
facility: Franciscan Children's Hospital
state: Massachusetts
Study officials:
affiliation: BU Goldman School of Dental Medicine, Pediatrics
name: Keri Discepolo, DDS MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00536770: A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Official title: A Randomized Phase 2 Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Subjects With Advanced Pancreatic Adenocarcinoma
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Pancreatic Cancer
Lead sponsor: Novacea
Sponsor class: INDUSTRY
Collaborators: name: Schering-Plough
First posted: 2007-09-28
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of locally advanced and unresectable, or metastatic pancreatic cancer
* Performance status 0, 1,or 2
* Adequate bone marrow, renal and hepatic function

Exclusion Criteria:

* Prior chemotherapy or radiation therapy for pancreatic cancer
* Prior treatment for other cancers in last 6 months
* Cancer of the brain or spine
* Active uncontrolled infection
* Hypercalcemia

Primary outcomes:
measure: Overall survival rate at 6 months
Secondary outcomes:
measure: Objective response rate
measure: Duration of progression free survival
measure: Duration of overall survival
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Novacea Investigational Site
state: Tennessee
Study officials:
References:
Clinical trial NCT03049670: The Use of Klorsept Solution for Debriding Infected Wounds: is it Effective and Safe? Prospective Observational Study
Official title: The Use of Klorsept Solution for Debriding Infected Wounds: is it Effective and Safe? Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-healing Wound
Infected Wound
Keywords: Safety Issue
Lead sponsor: Carmel Medical Center
Sponsor class: OTHER
First posted: 2017-02-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Males and females above the age of 18

Brief summary: Klorsept is a debridement solution of necrotic infected tissue promoting wound healing. The aim of this study is to elaborate the effectiveness and safety of this solution.

Detailed description: Klorsept is a debridement solution of necrotic infected tissue promoting wound healing. The aim of this study is to elaborate the effectiveness and safety of this solution.

This study will include 50 patients suffering from necrotic and infected wounds. Several parameters will be evaluated in order to provide the effectiveness and safety of this treatment.

Eligibility criteria: Inclusion Criteria:

* hospitalized patients with infected wounds who can sign an informed consent

Exclusion Criteria:

* patient that can not sign an informed consent
* pregnant woman
* age less than 18 years
* Allergy to chlorine

Primary outcomes:
measure: antiseptic properties
timeFrame: 1 year
Secondary outcomes:
measure: laboratory tests
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03677570: The Relationship Between Postural Stability, Performance and Trunk Muscle Endurance in Female Athletes
Official title: The Relationship Between Postural Stability, Performance and Trunk Muscle Endurance in Female Athletes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sports Physical Therapy
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2018-09-19
Enrollment: 60
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 45 female athletes and 15 healthy sedentary controls volunteered to take part in the study.

Brief summary: As core stability improves in handball players, ball-throwing speed increases as well. Postural stability is considered as the most important component of athletic performance as it occurs in almost all movement types. No studies have yet evaluated postural stability, performance and trunk muscle endurance in female athletes at the same time and examined the relationship between these parameters.This study aims to identify the relationship between the postural stability, performance and trunk muscle endurance of female athletes in different branches of sports.

Detailed description: A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) and 15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study. Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.

Eligibility criteria: Inclusion Criteria:

* Not being injured in the last 3 months
* Being a professional athlete that does training 5 days a week for the last two years

Exclusion Criteria:

* cardiovascular system diseases
* pregnant women were excluded

Primary outcomes:
measure: postural stability
timeFrame: Baseline assessment, no follow-up
measure: vertical jump test
timeFrame: Baseline assessment, no follow-up
measure: hexagonal obstacle test
timeFrame: Baseline assessment, no follow-up
measure: trunk flexion test
timeFrame: Baseline assessment, no follow-up
measure: trunk extension test
timeFrame: Baseline assessment, no follow-up
measure: prone bride test
timeFrame: Baseline assessment, no follow-up
measure: side bridge test
timeFrame: Baseline assessment, no follow-up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Faculty of Health Sciences, Department of Physical Therapy and Rehabilitation, Gazi University
name: nevin güzel, prof.dr
role: STUDY_CHAIR
References: